We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will summarize the bulls’ thesis on EW. Edwards Lifesciences Corporation (EW)’s share ...

Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.

US medical device giant Edwards Lifesciences has said patients are experiencing “outstanding one-year outcomes” and lower rates of mortality after treatment with its SAPIEN 3 RESILIA heart valve.

Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...

Edwards Lifesciences introduced TAVR to the U.S. back in November 2011 when FDA approved its Sapien heart valve for patients with aortic stenosis who were too sick to undergo open heart surgery.

Brighton Jones LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EW – Free Report) in the fourth quarter, ...

High-rolling investors have positioned themselves bullish on Edwards Lifesciences (NYSE:EW), and it's important for retail traders to take note. \This activity came to our attention today through ...

Edwards Lifesciences EW is developing the most comprehensive structural heart disease portfolio post the sell-off of the Critical Care wing. The Surgical Structural Heart business is benefiting ...

NEW YORK, December 04, 2024--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW ... TMTT’s portfolio of life-changing therapies including PASCAL, EVOQUE and SAPIEN M3 will drive multiple ...

NEW YORK, June 05, 2024--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR ...